A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP (NCT07119125)
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRT-8102 in Healthy Participants and in Participants at Cardiovascular Risk With Elevated CRP
π©Ί Plain-English Summary (8th-Grade Level)
The principal aim of this study is to obtain safety and tolerability data when MRT-8102 is administered orally as single and multiple doses to healthy participants and participants at cardiovascular risk with elevated CRP. This information, together with the pharmacokinetic (PK) data, will help establish the dose and dosing regimen suitable for future studies. The study drug, MRT-8102, is experimental. This is the first study in which MRT-8102 will be given to humans. Part 1: Healthy participants will receive a single oral dose of MRT-8102 or placebo on Day 1 Part 2: Healthy participants will receive multiple oral doses of MRT-8102 or placebo for 7 consecutive days Part 3: Participants at cardiovascular risk with elevated CRP will receive multiple oral doses of MRT-8102 or placebo for 28 consecutive days
Who can join: Review the eligibility criteria below.
Location: Clinical Pharmacology of Miami, LLC β Miami, Florida
Age range: 18 Years to 65 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (4 Sites)
- Clinical Pharmacology of Miami, LLC β Miami, Florida
- ICON Clinical Research β Lenexa, Kansas
- QPS β Springfield, Missouri
- Endeavor Clinical Trials β San Antonio, Texas
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Healthy Volunteers
- Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants β Hialeah, Florida
- A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants β Grayslake, Illinois
- Flavanol-rich Cocoa on Digestive and Cerebrovascular Health in the Colombian Adults β MedellΓn, Antioquia
- ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study β Bethesda, Maryland
- A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants β Mount Royal, Quebec
Explore by condition: All Healthy Volunteers clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.